Investing.com UK Article Rating

BrainsWay Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep ™S™ for Depression By Investing.com

Jun 10, 2024 View Original Article
  • Bias Rating

    6% Center

  • Reliability

    N/AN/A

  • Policy Leaning

    6% Center

  • Politician Portrayal

    N/A

Bias Score Analysis

The A.I. bias rating includes policy and politician portrayal leanings based on the author’s tone found in the article using machine learning. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral.

Sentiments

Overall Sentiment

4% Positive

  •   Conservative
SentenceSentimentBias
Unlock this feature by upgrading to the Pro plan.

Bias Meter

Extremely
Liberal

Very
Liberal

Moderately
Liberal

Somewhat Liberal

Center

Somewhat Conservative

Moderately
Conservative

Very
Conservative

Extremely
Conservative

-100%
Liberal

100%
Conservative

Bias Meter

Contributing sentiments towards policy:

48% : In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise.
47% : The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company's anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep ™S products; unforeseen difficulties with Deep ™S products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep ™S products; failure to obtain and maintain adequate protection of the Company's intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep ™S technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep ™S, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements.

*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.

Copy link